Yazar "Montrucchio, Giorgia" seçeneğine göre listele

Listeleniyor 1 - 1 / 1
  • Küçük Resim
    Öğe
    Different epidemiology of bloodstream infections in COVID-19 compared to non-COVID-19 critically ill patients: A descriptive analysis of the Eurobact II study
    (BioMed Central Ltd, 2022) Buetti, Niccolò; Tabah, Alexis; Loiodice, Ambre; Ruckly, Stéphane; Aslan, Abdullah Tarık; Montrucchio, Giorgia; Cortegiani, Andrea; Saltoğlu, Neşe; Kayaaslan, Bircan; Aksoy, Firdevs; Murat, Akova; Akdoğan, Özlem; Saraçoğlu, Kemal Tolga; Erdoğan, Cem; Leone, Marc; Ferrer, Ricard; Paiva, José-Artur; Hayashi, Yoshiro; Ramanan, Mahesh; Conway Morris, Andrew; Barbier, François; Timsit, Jean-François; Lipman, Jeffrey; Litton, Edward; Palermo, Anna Maria; Yap, Timothy; Eroğlu, Ege; Hosokawa, Koji; Yoshida, Hideki; Fujitani, Shigeki; Zand, Farid; Mahmoodpoor, Ata; Tabatabaei, Seyed Mohammad Nasirodin; Elrabi, Omar; Almekhlafi, Ghaleb A.; Vidal, Gabriela; Aparicio, Marta; Alonzo, Irene; Namendys-Silva, Silvio A.; Hermosillo, Mariana; Castillo, Roberto Alejandro; De Bus, Liesbet; De Waele, Jan; Hollevoet, Isabelle; De Schryver, Nicolas; Serck, Nicolas; Kovacevic, Pedja; Zlojutro, Biljana; Ruppe, Etienne; Montravers, Philippe; Dulac, Thierry; Castanera, Jérémy; Massri, Alexandre; Guesdon, Charlotte; Garcon, Pierre; Duprey, Matthieu; Philippart, François; Tran, Marc; Bruel, Cédric; Kalfon, Pierre
    Background: The study aimed to describe the epidemiology and outcomes of hospital-acquired bloodstream infections (HABSIs) between COVID-19 and non-COVID-19 critically ill patients. Methods: We used data from the Eurobact II study, a prospective observational multicontinental cohort study on HABSI treated in ICU. For the current analysis, we selected centers that included both COVID-19 and non-COVID-19 critically ill patients. We performed descriptive statistics between COVID-19 and non-COVID-19 in terms of patients’ characteristics, source of infection and microorganism distribution. We studied the association between COVID-19 status and mortality using multivariable fragility Cox models. Results: A total of 53 centers from 19 countries over the 5 continents were eligible. Overall, 829 patients (median age 65 years [IQR 55; 74]; male, n = 538 [64.9%]) were treated for a HABSI. Included patients comprised 252 (30.4%) COVID-19 and 577 (69.6%) non-COVID-19 patients. The time interval between hospital admission and HABSI was similar between both groups. Respiratory sources (40.1 vs. 26.0%, p < 0.0001) and primary HABSI (25.4% vs. 17.2%, p = 0.006) were more frequent in COVID-19 patients. COVID-19 patients had more often enterococcal (20.5% vs. 9%) and Acinetobacter spp. (18.8% vs. 13.6%) HABSIs. Bacteremic COVID-19 patients had an increased mortality hazard ratio (HR) versus non-COVID-19 patients (HR 1.91, 95% CI 1.49–2.45). Conclusions: We showed that the epidemiology of HABSI differed between COVID-19 and non-COVID-19 patients. Enterococcal HABSI predominated in COVID-19 patients. COVID-19 patients with HABSI had elevated risk of mortality. Trial registration ClinicalTrials.org number NCT03937245. Registered 3 May 2019.